Looks like you’re on the US site. Choose another location to see content specific to your location

Medication Expected to Accumulate $125 in Revenue by 2033
A group of obesity and type 2 Diabetes drugs called GLP-1 receptor agonists have been released for use in therapy.
GLP-1 receptor agonist sales are rising along with the marketplaces for Type 2 diabetes and obesity, which are expanding at previously unheard-of rates.
During the following decade Type 2 Diabetes and Obesity will control the market for metabolic illnesses.
Key opinion leaders surveyed stated that consumers typically seek their doctors for these medications since they are already well-liked.
At present, 3 GLP-1 receptor agonists and ten GLP-1 receptor agonists for Type 2 diabetes are permitted; however, in the coming 5 to 10 years, numerous additional medications are anticipated to hit the shelves.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard